The use of pro-brain natriuretic peptide targeted therapy [pro-BNP] to tailor medical management of patients with congestive heart failure [CHF] followed in an outpatient setting: the ProBNP outpatient tailored CHF therapy (PROTECT) study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Heart failure therapies
Indications Heart failure
Focus Therapeutic Use
Acronyms PROTECT

Most Recent Events

25 Mar 2019 Biomarkers information updated
26 Apr 2012 Planned end date changed from 1 Dec 2009 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
16 Nov 2011 Quality-of-life results presented at the 84th Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight